Sustained and improved guselkumab response in patients with active psoriatic arthritis regardless of baseline demographic and disease characteristics: Pooled results through week 52 of two phase III, randomised, placebo-controlled studies

Sustained and improved guselkumab response in patients with active psoriatic arthritis regardless of baseline demographic and disease characteristics: Pooled results through week 52 of two phase III, randomised, placebo-controlled studies

Objectives To evaluate the efficacy through 52 weeks of guselkumab, an interleukin 23-p19 subunit inhibitor, in subgroups of pooled psoriatic arthritis (PsA) patients from the DISCOVER-1 and DISCOVER-2 trials defined by baseline patient characteristics. Methods Adults with active PsA despite standar...

Full description

Bibliographic Details
Main Authors: Boehncke, W.-H (Author), Chakravarty, S.D (Author), Deodhar, A. (Author), Jiang, Y. (Author), Kollmeier, A.P (Author), McInnes, I.B (Author), Mease, P.J (Author), Merola, J.F (Author), Ritchlin, C.T (Author), Schiopu, E. (Author), Shawi, M. (Author), Sheng, S. (Author), Tesser, J. (Author), Wang, Y. (Author), Xu, S. (Author), Xu, X.L (Author)
Format: Article
Language:English
Published: BMJ Publishing Group 2022
Subjects:
arthritis, psoriatic
biological therapy
therapeutics
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items